Breast Care
Retrospective analysis of real-world elacestrant use in two large Austrian cancer centers
By Lisa Vesenmayer, Simon Udovica, Kerstin Wimmer and 10 others.
Abstract
Background
Elacestrant is an oral selective estrogen receptor degrader (SERD) approved for the treatment of hormone receptor–positive (HR-positive), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) following progression on endocrine therapy and CDK4/6 inhibitors. While randomized trial data from the EMERALD study demonstrated its clinical benefit, real-world evidence remains limited.
Methods
We conducted a retrospective chart review of patients with HR-positive/HER2-negative MBC treated with elacestrant at two large cancer centers in Vienna, Austria. Clinical outcomes and safety were evaluated in routine clinical practice by experienced oncologists.